Herken en faciliteer uw innovatieve medewerker! Een exploratieve casestudie bij Philips Research naar innovatief werkgedrag van werknemers in relatie met persoonskenmerken en contextuele werkfactoren

Wat maakt dat sommige medewerkers vanuit zichzelf innovaties initiëren en welke invloed hebben contextuele werkfactoren daarop? In de literatuur is een groeiende belangstelling voor de individuele mens die uit zichzelf innoveert. Dit zijn medewerkers die creatief zijn en bestand tegen weerstand van collega's, managers of de organisatie als geheel die van nature streven naar behoud van het bekende (Van Hootegem 1999; Vermeulen 2011).<br/> In dit artikel doen wij verslag van een casestudie bij Philips Research in Eindhoven, waar research en development plaats vindt. Zeven managers en zevenentwintig medewerkers op vier afdelingen zijn tussen oktober 2018 en december 2019 geïnterviewd in een kwalitatieve casestudie. De in de literatuur genoemde creatieve en psychologische empowerment persoonskenmerken met bijbehorende determinanten blijken herkenbaar in de interviews bij medewerkers met innovatief werkgedrag (IWG). Daarnaast vertonen de medewerkers met IWG een verschillende mate van innovatie energie. Een optimistische natuur helpt om standvastig door te zetten als hindernissen overwonnen moeten worden. Het hebben van contacten met de buitenwereld (waaronder cocreatie met stakeholders) en ruimte voor autonomie stimuleert hun IWG. De leidinggevende speelt hierbij een ondersteunende rol. Aanbevolen wordt om bij werving, selectie en coaching de persoonskenmerken van een medewerker met IWG en de kenmerken van ondersteunend leiderschap te benutten, in functieprofielen te benoemen welke specifieke innovatiekwaliteiten gewenst zijn, ruimte te bieden voor autonomie, externe contacten te stimuleren waaronder cocreatie en terughoudend te zijn met een bonussysteem in relatie met innovatie en meer aandacht te hebben voor intrinsieke innovatie stimuli.

New developments in optical sensing technology: an interview with Adrien Desjardins

Adrien has a PhD from Harvard and the Massachusetts Institute of Technology (both MA, USA) in biomedical engineering and biophysics, with a specific focus on cardiovascular devices, fiber optic sensing and optical coherence tomography. After his PhD, he led technical developments in an internal venture at Philips Research (Eindhoven, Netherlands) to develop devices with integrated optical sensors and brought this technology from benchtop prototypes to in vivo human studies. In addition to his responsibilities at Echopoint Medical (London, UK) where he is Chief Technology Officer, Adrien is also is a Professor of Biomedical Engineering at University College London (London, UK), where he leads the interventional devices group with a vision to develop novel methods for performing physiological measurements and imaging with minimally invasive devices. He has over 52 patent applications and granted patents.

Long-Term Outcomes for G-CSF Treatment of Patients with Glycogen-Storage Disease Type Ib

Background: Glycogen-storage disease 1b (GSD 1b) is characterized by neutropenia, hepatomegaly, hypoglycemia, enterocolitis and recurrent severe infections. For more than 25 years, many GSD 1b patients worldwide have been treated with granulocyte colony-stimulating factor (G-CSF). Methods: The Severe Chronic Neutropenia International Registry (SCNIR) enrolls and prospectively follows GSD 1b patients with both severe (ANC&lt; 0.5 x 109/L) and mild or moderate neutropenia (ANC&lt; 1.5 x 109/L). For this report we analyzed records for 83 patients enrolled through the SCNIR offices in Seattle, Washington and Hannover, Germany. Findings - Clinical outcomes: Overall most patients and parents report very favorable outcomes with increases in neutrophils, reduced infections, reduced symptoms of enterocolitis and improved quality of life. Neutropenia: Because splenomegaly may increase markedly with G-CSF treatment, clinical experience dictates that the G-CSF dose should be carefully monitored to maintain the ANC at 1.0 to 2.0 x 109/L. Summary data for treatment of 83 patients are shown in Table 1. Myeloid malignancies: We assessed the risk of GSD 1b patients developing myeloid malignancies from review of the medical literature and patients prospectively followed through the SCNIR. We identified 1 case of AML prior to availability of G-CSF and 6 cases of AML in G-CSF treated patients, 4 from the cohort followed prospectively by the SCNIR. Table 2 shows detailed data for the 7 patients with GSD1b who have developed AML. Conclusions: In the 83 SCNIR patients followed for a mean (median) of 12.2 (11.0) years there are 4 cases (4/83, 4.8%) of AML, or 1 case/253 years of G-CSF treatment. This is lower than the estimated risk of evolution to AML in the major genetic subgroups of severe congenital neutropenia treated with G-CSF, e.g., harboring ELANE, HAX1, SDS mutations . The numbers of patients in other genetic subgroups, such as G6PC3, JAGN1, TCIRG1, etc. are too small to make any reliable comparison about the risk of developing leukemia. (Skokowa J et al. Nat Rev Dis Primers. 2017 Jun 8. doi: 10.1038/nrdp.2017.32. [Epub ahead of print]). Disclosures Dale: Amgen: Consultancy, Research Funding; Sanofi Aventis: Consultancy, Editor, Current Opinions in Hematology, Honoraria; Cellerant: Membership on an entity's Board of Directors or advisory committees; Genzyme (now owned by Sanofi-Aventis): Consultancy, Patents & Royalties, Research Funding; Genkyotex: Other: DSMB (work completed 6/2015); Hospira: Consultancy; Prolong: Consultancy; Boheringer-Ingelheim: Consultancy; Coherus: Consultancy; Omeros: Other: DSMB; Shire: Other: Independent Review Board; X4Pharma: Research Funding; Philips: Research Funding; Wolter Kluwer: Other: Editor, Current Opinions in Hematology; WedMD/Medscape: Membership on an entity's Board of Directors or advisory committees; National Institutes of Health: Research Funding; University of Washington: Employment, Research Funding; American College of Physicians: Other: Editor and author; GlaxoSmithKline: Equity Ownership; Johnson&Johnson: Equity Ownership. Weinstein: Vitaflo: Research Funding; Dimension Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding.

Integration of a Robotic Endoscope Holder with the Surgical Assistant Workstation Software Framework

We have integrated the Philips Research robot arm with the Johns Hopkins cisst library, an open-source platform for computer assisted surgical intervention, for assistance during minimally invasive cardiac surgery using image-based steering of an endoscope. The development of a Matlab to C++ wrapper to abstract away servo-level details facilitates the rapid development of a component-based framework with “plug and play” features. This allows the user to easily exchange the robot with an alternative manipulator while maintaining the same overall functionality.